DDC and Parkinson disease: Benserazide, an FDA‐approved Pkm2 inhibitor that inhibits peripheral dopa decarboxylase for the treatment of Parkinson's disease, has a weak effect on the induction of apoptosis; however, our results show that benserazide is still involved in combination therapy with Raf1.